Selva Therapeutics is advancing SLV213, an orally available small‑molecule antiviral that blocks host cysteine protease cathepsin L to prevent viral entry. SLV213 has shown broad and potent activity in preclinical studies against SARS‑CoV‑2 and other viruses including SARS, Ebola, and Nipah, and has completed preclinical IND‑enabling safety studies. The company is first advancing SLV213 as an oral candidate for COVID‑19 to enable outpatient and prophylactic use, though it can also be dosed intravenously. SLV213 was developed from UC San Diego research and is exclusively licensed to Selva. Selva is headquartered in San Diego and recently raised financing to support clinical development.

Total raised

$3M

Funding rounds

1

Latest round

Series A

Latest activity

Jul 2020